446286-25-5 Usage
Uses
Used in Organic Synthesis:
2-Chloro-4-(tributylstannyl)pyrimidine is utilized as a reagent in organic synthesis for the functionalization of pyrimidine rings. Its unique structure allows for the introduction of various functional groups, enhancing the versatility of pyrimidine-based compounds for different applications.
Used in Pharmaceutical Synthesis:
As a precursor, 2-Chloro-4-(tributylstannyl)pyrimidine is employed in the synthesis of pharmaceuticals. Its ability to be modified and functionalized makes it a valuable component in the development of new drugs with specific therapeutic properties.
Used in Agrochemical Synthesis:
Similarly, 2-Chloro-4-(tributylstannyl)pyrimidine is used as a precursor in the synthesis of agrochemicals. Its contribution to the development of effective and targeted agrochemicals is significant, particularly in the creation of compounds that can address various agricultural challenges.
Check Digit Verification of cas no
The CAS Registry Mumber 446286-25-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,6,2,8 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 446286-25:
(8*4)+(7*4)+(6*6)+(5*2)+(4*8)+(3*6)+(2*2)+(1*5)=165
165 % 10 = 5
So 446286-25-5 is a valid CAS Registry Number.
InChI:InChI=1/C4H2ClN2.2C4H9.C3H7.Sn/c5-4-6-2-1-3-7-4;2*1-3-4-2;1-3-2;/h1-2H;2*1,3-4H2,2H3;1,3H2,2H3;/rC15H27ClN2Sn/c1-4-7-12-19(11-6-3,13-8-5-2)14-9-10-17-15(16)18-14/h9-10H,4-8,11-13H2,1-3H3
446286-25-5Relevant articles and documents
Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
-
Page 109, (2008/06/13)
This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.